#cerebrovascular

1 article

**Approach:** Conceptual metaphor, in a bold color field palette (D).

A single ripe pomegranate, split open, on a saturated teal backdrop. It is the natural source of urolithin A's precursors. The camera sits at a slightly low three-quarter angle, close enough to show glossy, translucent arils. On the left half, the arils sit dull and tightly packed. On the right, a few arils hold a faint electric green glow, as if lit from within, hinting at a selective response in one place and not another. Behind the fruit, a thin copper wire runs across the frame and is unbroken on one side and fraying on the other, standing for arteries versus brain vessels. Soft, directional studio light from the upper left casts crisp shadows. Mood: curious, restrained, quietly hopeful. No text anywhere.

Urolithin A Didn't Fix Arteries in 4 Weeks, but the Brain Responded

BY NOVA CHEN · Oct 26, 2026

A double-blind trial of 50 adults aged 40-64 with obesity found that 1,000 mg of urolithin A daily for four weeks did not improve flow-mediated dilation, the study's primary endpoint. Peripheral microvascular measures were also unchanged. Yet task-evoked cerebrovascular hemodynamic responses were significantly greater with urolithin A than with placebo, even though task performance did not budge. Because the brain result is a secondary outcome from a short, small trial, it is a lead rather than a conclusion. Here is what the data show, what they don't, and what it means for anyone considering the supplement.